Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains

Full text
Seabra, Gabriela [1] ; Falvella, Ana Caroline B. [1] ; Guest, Paul C. [1] ; Martins-de-Souza, Daniel [2, 1] ; de Almeida, Valeria [1]
Total Authors: 5
[1] Univ Estadual Campinas, UNICAMP, Lab Neuroprote, Dept Biochem & Tissue Biol, Inst Biol, Campinas, SP - Brazil
[2] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBION, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Review article
Source: PROTEOMICS; v. 18, n. 18, SI SEP 2018.
Web of Science Citations: 0

Interest in the modulation of endocannabinoid signaling has increased since the discovery of receptors for compounds of Cannabis sativa. Endocannabinoids are crucial neuromodulators of many brain functions and changes in the ligands and their receptors have been associated with psychiatric disorders, such as schizophrenia. Genetic, neuroimaging, and behavioral studies have reinforced the role of endocannabinoids in the pathobiology of schizophrenia. However, molecular pathways and biological processes involved in cannabinoid effects are not totally understood. Additionally, the endocannabinoid signaling network with other non-cannabinoid targets, and the effects of phytocannabinoids increase the complexity to understand their role in schizophrenia and homeostasis conditions. Thus, proteomic studies can provide evidence about the involvement of cannabinoid receptors, as well as the metabolic and synthetic enzymes of the endocannabinoids in these disorders. Additionally, quantification of endocannabinoids in the blood serum or cerebrospinal fluid can be a useful approach to identify new biomarkers in schizophrenia, and lipidomic techniques can be used to quantify these compounds. Herein, the authors review proteomic and lipidomic studies that have been used for analysis of the endocannabinoid system in healthy and schizophrenia function. The findings may contribute to understand the involvement of endocannabinoids in the brain and in the neurobiological basis of schizophrenia. (AU)

FAPESP's process: 17/18242-1 - Biochemical pathways affected by cannabinoid drugs of human oligodendrocytes
Grantee:Valéria de Almeida
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 18/03673-0 - Biochemical effects of cannabinoids on oligodendrocytes: implications for schizophrenia
Grantee:Daniel Martins-de-Souza
Support Opportunities: Regular Research Grants
FAPESP's process: 18/10362-0 - Evaluation of the effect of antipsychotics and the cannabidiol in an oligodendrocytes culture treated with cuprizone: implications for myelination
Grantee:Ana Caroline Brambilla Falvella
Support Opportunities: Scholarships in Brazil - Master